InstantWhyThe deal
Skyworks Solutions announced that the Hart-Scott-Rodino antitrust waiting period for its merger with Qorvo has expired, according to Seeking Alpha. The HSR Act requires companies to notify federal regulators of large transactions and wait a set period while the FTC and Justice Department review for competitive concerns. Expiration of the waiting period means regulators raised no objection and the companies may proceed, though other closing conditions may remain.
Why it matters
The deal still requires shareholder approval and satisfaction of other standard closing conditions, but antitrust review was the biggest uncertainty — regulators can and do block semiconductor mergers when they see market concentration risk. With that clock now run, the transaction moves from regulatory risk to execution risk.
Deal context
Bank of America cut its Skyworks price target in late July, citing concerns about merger execution. The HSR waiting period is typically thirty days but can be extended if regulators request additional information through a second request, which did not happen here. Earlier in the summer, quantum computing firm IonQ completed its acquisition of chip fabricator SkyWater after receiving FTC clearance, showing regulators are reviewing semiconductor deals closely but not blocking them uniformly.
What has to happen next
Skyworks and Qorvo will work toward satisfying remaining closing conditions, which typically include shareholder votes and final contractual requirements. The companies have not disclosed an expected closing date. Investors will watch for any disclosure of deal terms or integration plans as the transaction nears completion.
- ✓Detected and written at 2026-08-03 11:41
- ✓First reported by Seeking Alpha
- ✓Written from public facts in our own words — never a copy
- ✓Published as fast as possible; our team holds editorial responsibility
Sources
- Seeking Alpha — Market Currents: https://seekingalpha.com/news/4623338-skyworks-solutions-says-hsr-waiting-period-for-qorvo-merger-has-expired?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
More stories
InstantWhyAstraZeneca leads pharma revenue growth as Bristol Myers lags, complicating merger logic
InstantWhySpaceX shares under pressure ahead of first earnings report since IPO
InstantWhy